GLP-1 receptor agonists, the medications behind Ozempic, Wegovy, Mounjaro, and Zepbound, are showing remarkable early promise for reducing cravings across multiple substances, including opioids, alcohol, and nicotine. In the first randomized, placebo-controlled trial of its kind, patients in residential treatment for opioid use disorder who received a GLP-1 medication reported a 40 percent reduction in opioid craving compared to placebo, beginning in the first week of treatment. A separate randomized trial published in JAMA Psychiatry found that weekly semaglutide injections reduced alcohol craving, drinking quantity, and the frequency of heavy drinking days in adults with alcohol use disorder. These medications are not yet FDA approved for addiction, but they may represent the biggest shift in how we understand craving in a generation.
A New Way of Thinking About Craving
For most of the last century, craving was treated as a failure of willpower. Then it was treated as a psychological symptom. The GLP-1 research suggests something different: craving may function as a biological need state, processed by the same brain circuitry that produces hunger and thirst.
GLP-1 is a natural hormone, a satiety signal that tells the brain a need has been met. Researchers at Penn State College of Medicine proposed that addiction hijacks these same "need pathways," meaning the brain begins registering the substance as a survival requirement, like food or water. If that is true, then a medication that satisfies the body's need signaling could quiet drug or alcohol craving the same way a meal quiets hunger.
This reframing matters beyond the pharmacology. It says what people in recovery have long known from the inside: craving is not a character flaw. It is a signal from a nervous system that has reorganized itself around a substance. And signals can be turned down.
What the Research Shows for Opioids
The Penn State trial, conducted in a residential treatment facility, tracked craving in real time by pinging participants on their phones four times a day. The findings went beyond the headline number. The 40 percent reduction in craving was equivalent to what researchers had previously seen after two weeks of intensive residential treatment. The medication worked even at the lowest dose and even when patients reported high stress. Patients on placebo typically experienced craving spikes in the afternoon and evening, while craving among those on the GLP-1 stayed flat. Among participants also taking buprenorphine, the GLP-1 significantly increased the probability of reporting no opioid cravings at all by the tenth day.
The real-world data points the same direction. A study involving over one million patients found that those taking GLP-1 receptor agonists experienced lower rates of opioid overdose and alcohol intoxication, published in the journal Addiction. A larger trial of semaglutide in 200 patients on methadone or buprenorphine is now underway across three states. For context on what opioid withdrawal itself involves, see our opioid detox guide.
What the Research Shows for Alcohol
The alcohol findings may be the most advanced of all, and they began with patients themselves. After Ozempic exploded in popularity, doctors kept hearing the same unexpected report: people started weekly injections for obesity or diabetes and suddenly lost their desire for alcohol.
That observation is now confirmed by controlled research. In a phase 2, double-blind randomized trial published in JAMA Psychiatry, adults with alcohol use disorder who received low-dose semaglutide for nine weeks consumed significantly less alcohol in a laboratory self-administration test than those on placebo, with medium to large effect sizes. Semaglutide significantly reduced drinks per drinking day and weekly alcohol craving relative to placebo, even at doses far below what is typically prescribed for weight loss.
The stakes are enormous. Alcohol claims the lives of 178,000 people in the United States every year, and the few medications approved for alcohol use disorder are rarely prescribed. Because alcohol withdrawal can be medically dangerous, any reduction strategy should begin with a supervised plan, not abrupt quitting.
What About Nicotine, Cocaine, and Other Substances?
The same reward circuitry runs through nearly every addiction, and early signals are appearing across the board. In the JAMA Psychiatry alcohol trial, participants who smoked also reduced their cigarettes per day. Research links GLP-1 use to roughly 20 to 26 percent lower cocaine use, and a 2026 study found GLP-1 medications associated with a 14 percent lower risk of cannabis use disorder. Early reports even suggest reductions in compulsive behaviors such as gambling and binge shopping, although that evidence remains mostly anecdotal. A recent systematic review counted 33 registered clinical trials studying GLP-1s for substance use disorders.
The Two Hungers of Early Recovery
There is a second reason GLP-1s fit recovery so naturally. When a substance leaves the body, two appetites return at once.
The first is for food. Opioids suppress appetite and dull the taste for regular meals, and alcohol delivers hundreds of empty calories a day that the body suddenly misses. After detox, hunger comes back with force, and it often comes back craving sugar, which stimulates some of the same reward circuits the brain is missing. Significant weight gain in the first months of recovery is one of the most common and least discussed challenges people face, and for some it becomes a source of shame that threatens sobriety itself.
The second hunger is for the substance. Both hungers run through overlapping reward pathways. A medication that moderates one may help moderate the other, which is exactly what the early data suggests. For people whose post-detox weight gain is affecting their health or self-worth, a physician-supervised GLP-1 may serve a dual purpose: healthy weight management and a potential reduction in the background noise of craving.
What to Know Before Considering a GLP-1 in Recovery
They are not approved for addiction. GLP-1 drugs show real potential for reducing cravings, but FDA approval for addiction treatment is still pending. Any use for this purpose today is off-label and must be guided by a physician who knows your full history.
They do not replace recovery care. GLP-1s are being studied as an addition to evidence-based treatment, not a substitute for medical detox, medication-assisted treatment, or counseling. Detox addresses physical dependence, as our withdrawal symptoms guide explains; recovery addresses everything that comes after. For ongoing medication options like buprenorphine and methadone, see OpioidTreatmentFinder.com's treatment guides.
Side effects are real. Nausea, vomiting, constipation, and appetite suppression are common, and while often manageable, they can be therapy-ending. In the Penn State trial, patients taking both the GLP-1 and buprenorphine had fewer stomach issues and were less likely to drop out, suggesting combination therapy may be more tolerable.
The benefits require continuity. Research published in The Lancet's eClinicalMedicine found that about 60 percent of weight lost on GLP-1s is regained within one year of stopping, and craving benefits appear to fade as well. Patients who paired the medication with supervised exercise regained significantly less weight after stopping than those on medication alone. These medications work as part of a structured plan with built-in lifestyle support, not as a standalone fix.
The Bottom Line
The GLP-1 story is still being written, but its deeper message is already clear. Craving is biology, not weakness. Whether the substance is opioids, alcohol, or nicotine, the same science that helped millions quiet food noise may soon help people in recovery quiet something far more dangerous. Until the trials are complete, the right move is a conversation with a physician who understands both addiction medicine and metabolic health, alongside a complete recovery plan.
If you or someone you love needs help now, SAMHSA's National Helpline (1-800-662-4357) is free, confidential, and available 24/7.
Frequently Asked Questions
Can Ozempic reduce alcohol cravings?
Early evidence says yes. In a randomized trial published in JAMA Psychiatry, weekly semaglutide injections reduced alcohol craving, drinking quantity, and heavy drinking days compared to placebo, even at low doses. Semaglutide is not FDA approved for alcohol use disorder, and larger trials are underway.
Can GLP-1 drugs reduce opioid cravings?
Possibly. In a randomized, placebo-controlled trial, patients receiving a GLP-1 medication showed a 40 percent reduction in opioid craving compared to placebo. Larger follow-up trials are in progress.
Do GLP-1s help with other substances like nicotine or cocaine?
Early research suggests they might. Trial participants reduced cigarettes per day, and observational studies link GLP-1s to lower cocaine and cannabis use. This evidence is preliminary.
Why do people gain weight after detox?
Opioids suppress appetite and alcohol supplies empty calories. When the substance clears, appetite rebounds, often with strong sugar cravings, because sugar activates some of the same reward pathways. Weight gain in early recovery is common and normal.
Do GLP-1s replace buprenorphine, methadone, or other treatment?
No. They are being studied as an addition to proven treatments, not a replacement. In trials, combining a GLP-1 with buprenorphine actually improved tolerability and retention.